Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secondary Exposure to Nestorone + Testosterone Gel
NCT02994602Phase 1Completed
- Start
- Jan 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of segesterone acetate + testosterone and Testosterone TEPI patch in male contraception. Primary endpoints: Average serum testosterone concentration in females at 17 days and Maximum serum testosterone concentration in females at 17 days. Started Jan 2017; status: completed.
02
Drugs
segesterone acetate + testosteroneTestosterone TEPI patch
03
Conditions
male contraception
Beyond the preview
Go deeper on NCT02994602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02994602.